|
US8629246B2
(en)
|
2007-09-26 |
2014-01-14 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
|
WO2010035012A1
(en)
*
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
|
BRPI1008692B8
(pt)
|
2009-02-17 |
2021-05-25 |
Ucb Biopharma Sprl |
anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
|
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
|
US20120177651A1
(en)
*
|
2009-05-28 |
2012-07-12 |
Neil James Clarke |
Antigen-binding proteins
|
|
US9394374B2
(en)
*
|
2009-05-28 |
2016-07-19 |
Glaxo Group Limited |
Antigen-binding proteins
|
|
WO2010141329A1
(en)
*
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
ES2667258T3
(es)
*
|
2009-09-10 |
2018-05-10 |
Ucb Biopharma Sprl |
Anticuerpos multivalentes
|
|
GB201005063D0
(en)
*
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
GB0920127D0
(en)
*
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
|
GB201000467D0
(en)
*
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
EP2596114A4
(en)
*
|
2010-07-14 |
2014-01-08 |
Amgen Inc |
IMMUNOGLOBULIN WITH DOMAIN INSERTION
|
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
SG190362A1
(en)
|
2010-11-24 |
2013-06-28 |
Glaxo Group Ltd |
Multispecific antigen binding proteins targeting hgf
|
|
WO2012072731A2
(en)
|
2010-12-01 |
2012-06-07 |
Glaxo Group Limited |
Improved anti-serum albumin binding single variable domains
|
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
|
ME02734B
(me)
|
2011-01-14 |
2017-10-20 |
Ucb Biopharma Sprl |
Antitelo koje vezuje il-17a i il-17f
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
EP3626739A1
(en)
*
|
2011-06-24 |
2020-03-25 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
HUE035674T2
(en)
|
2011-07-13 |
2018-05-28 |
Ucb Biopharma Sprl |
Bacterial host strain expressing recombinant dsbc
|
|
BR112014006175B1
(pt)
|
2011-09-16 |
2020-02-11 |
Ucb Pharma S.A. |
Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
US9803004B2
(en)
|
2011-11-11 |
2017-10-31 |
Ucb Biopharma Sprl |
Albumin binding antibodies and binding fragments thereof
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
GB201208367D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Biological product
|
|
ES2711554T3
(es)
*
|
2012-05-22 |
2019-05-06 |
Bristol Myers Squibb Co |
Anticuerpos biespecíficos contra IL-17A/F IL-23 y sus usos
|
|
EP4001307A1
(en)
*
|
2012-12-17 |
2022-05-25 |
Cell Medica Inc. |
Antibodies against il-1 beta
|
|
GB201223276D0
(en)
*
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
JP6499087B2
(ja)
|
2013-02-26 |
2019-04-10 |
ロシュ グリクアート アーゲー |
二重特異性ｔ細胞活性化抗原結合分子
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
JP6449272B2
(ja)
*
|
2013-07-08 |
2019-01-09 |
ナンジン レジェンド バイオテック カンパニー，リミテッドＮａｎｊｉｎｇ Ｌｅｇｅｎｄ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． |
タンパク質の血清半減期を増加する組成物及び方法
|
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
|
MX371328B
(es)
*
|
2013-08-30 |
2020-01-27 |
Aprilbio Co Ltd |
Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion.
|
|
WO2015048685A1
(en)
*
|
2013-09-30 |
2015-04-02 |
Becton, Dickinson And Company |
Blocking reagent compositions and methods of making and using the same
|
|
SG11201602887QA
(en)
|
2013-10-25 |
2016-05-30 |
Psioxus Therapeutics Ltd |
Oncolytic adenoviruses armed with heterologous genes
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
EP3107569A4
(en)
|
2014-02-20 |
2018-02-21 |
Alder Biopharmaceuticals, Inc. |
Anti-acth antibodies and use thereof
|
|
JP6775422B2
(ja)
|
2014-03-28 |
2020-10-28 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
|
|
CA2944767C
(en)
|
2014-04-04 |
2022-07-12 |
Mayo Foundation For Medical Education And Research |
Isotyping immunoglobulins using accurate molecular mass
|
|
GB201406608D0
(en)
|
2014-04-12 |
2014-05-28 |
Psioxus Therapeutics Ltd |
Virus
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
GB201411420D0
(en)
*
|
2014-06-26 |
2014-08-13 |
Ucb Biopharma Sprl |
Antibody constructs
|
|
KR20170010863A
(ko)
|
2014-07-01 |
2017-02-01 |
화이자 인코포레이티드 |
이중특이성 이종이량체성 디아바디 및 이의 용도
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
EP3587446A1
(en)
*
|
2014-09-19 |
2020-01-01 |
City of Hope |
Costimulatory chimeric antigen receptor t cells targeting il13 r alpha 2
|
|
SG11201704283PA
(en)
*
|
2014-11-26 |
2017-06-29 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
JP2017536830A
(ja)
|
2014-11-26 |
2017-12-14 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
WO2016110576A1
(en)
|
2015-01-08 |
2016-07-14 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
EP3283522A1
(en)
*
|
2015-04-17 |
2018-02-21 |
Spring Bioscience Corporation |
Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
|
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
|
EP3288584A2
(en)
|
2015-04-30 |
2018-03-07 |
President and Fellows of Harvard College |
Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
|
MX383614B
(es)
|
2015-05-21 |
2025-03-14 |
Harpoon Therapeutics Inc |
Proteinas de union triespecificas y metodos de uso.
|
|
JP6851322B2
(ja)
|
2015-05-27 |
2021-03-31 |
ユーシービー バイオファルマ エスアールエル |
神経疾患を治療する方法
|
|
CN106188305A
(zh)
*
|
2015-06-01 |
2016-12-07 |
中山大学 |
具有融合至常规Fab片段的单域抗原结合片段的二价抗体
|
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
|
CR20210429A
(es)
|
2015-06-24 |
2021-09-24 |
Hoffmann La Roche |
ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
|
|
EA037092B1
(ru)
|
2015-07-06 |
2021-02-04 |
Юсб Биофарма Срл |
Тау-связывающие антитела
|
|
MX2017015908A
(es)
|
2015-07-06 |
2018-03-15 |
Ucb Biopharma Sprl |
Anticuerpos de union a tau.
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
TWI819458B
(zh)
*
|
2015-10-02 |
2023-10-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
DK3359688T3
(da)
|
2015-10-05 |
2021-08-23 |
Biogen Ma Inc |
Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme
|
|
MY207225A
(en)
|
2015-10-27 |
2025-02-06 |
UCB Biopharma SRL |
Methods of treatment using anti-il-17a/f antibodies
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
|
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
|
IL298686A
(en)
|
2016-01-11 |
2023-01-01 |
Inhibrx Inc |
Multivalent and multispecific ox40-binding fusion proteins
|
|
GB201602414D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Biological materials and uses thereof
|
|
JP7034489B2
(ja)
|
2016-03-15 |
2022-03-14 |
アイタブメッド （エイチケイ） リミテッド |
多重特異性Ｆａｂ融合タンパクおよびその使用
|
|
CA3022494A1
(en)
*
|
2016-05-01 |
2017-11-09 |
Ucb Biopharma Sprl |
Affinity engineered serum protein carrier binding domain
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
AU2017267793B2
(en)
|
2016-05-20 |
2024-01-25 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
US10100106B2
(en)
|
2016-05-20 |
2018-10-16 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
|
MA45255A
(fr)
|
2016-06-14 |
2019-04-17 |
Xencor Inc |
Anticorps inhibiteurs de points de contrôle bispécifiques
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
UA128304C2
(uk)
|
2016-07-14 |
2024-06-05 |
Ґенмаб А/С |
Мультиспецифічне антитіло до cd40 і cd137
|
|
MY197324A
(en)
|
2016-08-29 |
2023-06-13 |
Akamis Bio Ltd |
Adenovirus armed with bispecific t cell activator
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
BR112019007281A2
(pt)
|
2016-10-14 |
2019-07-09 |
Xencor Inc |
proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
|
|
WO2018083258A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding at least three transgenes
|
|
WO2018083257A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
|
US10844134B2
(en)
|
2016-11-23 |
2020-11-24 |
Harpoon Therapeutics, Inc. |
PSMA targeting trispecific proteins and methods of use
|
|
KR102275008B1
(ko)
|
2016-11-23 |
2021-07-13 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
|
GB201621728D0
(en)
|
2016-12-20 |
2017-02-01 |
Ucb Biopharma Sprl |
Methods
|
|
US20200087390A1
(en)
|
2016-12-21 |
2020-03-19 |
Amgen Inc. |
Anti-tnf alpha antibody formulations
|
|
US10266578B2
(en)
|
2017-02-08 |
2019-04-23 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
PT3592769T
(pt)
|
2017-03-09 |
2024-07-31 |
Genmab As |
Anticorpos contra pd-l1
|
|
WO2018183366A1
(en)
|
2017-03-28 |
2018-10-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
|
SG11201908772TA
(en)
|
2017-03-31 |
2019-10-30 |
Genmab Holding B V |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
AU2018265856B2
(en)
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
CA3063362A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
EP3624848A1
(en)
|
2017-05-19 |
2020-03-25 |
Syndax Pharmaceuticals, Inc. |
Combination therapies
|
|
JP7394628B2
(ja)
|
2017-06-01 |
2023-12-08 |
アカミス バイオ リミテッド |
腫瘍溶解性ウイルスおよび方法
|
|
WO2019004943A1
(en)
|
2017-06-30 |
2019-01-03 |
Aslan Pharmaceuticals Pte Ltd |
METHOD OF TREATMENT USING ANTIBODY DIRECTED AGAINST IL-13R
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
IL272159B2
(en)
|
2017-08-04 |
2026-03-01 |
Genmab As |
PD-L1 and CD137 binding agents and their use
|
|
SG11202002982YA
(en)
|
2017-10-10 |
2020-04-29 |
Numab Therapeutics AG |
Multispecific antibody
|
|
EP3470426A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispecific antibody
|
|
SI3694529T1
(sl)
|
2017-10-13 |
2024-10-30 |
Harpoon Therapeutics, Inc. |
Trispecifične beljakovine in načini uporabe
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
AU2018390418B2
(en)
|
2017-12-19 |
2023-12-21 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
JP7657591B2
(ja)
|
2017-12-22 |
2025-04-07 |
アルジェニクス ビーブイ |
二重特異性抗原結合コンストラクト
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
|
WO2019179391A1
(en)
*
|
2018-03-19 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific pd-1/ctla-4 antibody molecules
|
|
US12415843B2
(en)
*
|
2018-03-19 |
2025-09-16 |
The Regents Of The University Of California |
Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer
|
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
BR112020023330A2
(pt)
|
2018-05-14 |
2021-04-20 |
Harpoon Therapeutics, Inc. |
porção de ligação para ativação condicional de moléculas de imunoglobulina
|
|
SG11202012312UA
(en)
|
2018-06-18 |
2021-01-28 |
UCB Biopharma SRL |
Gremlin-1 antagonist for the prevention and treatment of cancer
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
CN112601761A
(zh)
|
2018-08-13 |
2021-04-02 |
印希比股份有限公司 |
结合ox40的多肽及其用途
|
|
CN112930356B
(zh)
|
2018-08-21 |
2025-03-21 |
奇特里尔私人有限公司 |
与瓜氨酸化的组蛋白2a和/或4结合的抗体
|
|
US12460000B2
(en)
|
2018-09-07 |
2025-11-04 |
Itabmed (Hk) Limited |
Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
EP3856771A4
(en)
|
2018-09-25 |
2022-06-29 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
US20240252635A1
(en)
|
2018-10-04 |
2024-08-01 |
Genmab Holding B.V. |
Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
|
|
MA53903A
(fr)
|
2018-10-16 |
2021-08-25 |
UCB Biopharma SRL |
Méthode de traitement de la myasthénie grave
|
|
GB201817311D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201817309D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
|
AU2019375014A1
(en)
|
2018-11-06 |
2021-05-27 |
Genmab A/S |
Antibody formulation
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
|
TWI756621B
(zh)
*
|
2019-01-25 |
2022-03-01 |
大陸商信達生物製藥（蘇州）有限公司 |
新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
|
|
CN121971599A
(zh)
|
2019-02-25 |
2026-05-05 |
芝加哥大学 |
用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
|
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
KR20220008866A
(ko)
|
2019-05-14 |
2022-01-21 |
하푼 테라퓨틱스, 인크. |
EpCAM 결합 단백질 및 사용 방법
|
|
CN113416258B
(zh)
*
|
2019-10-24 |
2023-08-29 |
北京免疫方舟医药科技有限公司 |
一种多特异性抗体及其制备方法和用途
|
|
EP3816185A1
(en)
|
2019-11-04 |
2021-05-05 |
Numab Therapeutics AG |
Multispecific antibody directed against pd-l1 and a tumor-associated antigen
|
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
|
CN110950967B
(zh)
*
|
2019-12-13 |
2022-05-13 |
山东民康生物科技有限公司 |
抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
|
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
|
GB202001447D0
(en)
|
2020-02-03 |
2020-03-18 |
Ucb Biopharma Sprl |
Antibodies
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
CN115335406B
(zh)
*
|
2020-02-12 |
2026-01-30 |
伊莱利利公司 |
抗体或抗原-结合片段的结晶
|
|
EP4103611B1
(en)
|
2020-02-13 |
2024-03-27 |
UCB Biopharma SRL |
Bispecific antibodies binding hvem and cd9
|
|
EP4103608A1
(en)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd137
|
|
EP4103610A1
(en)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Anti cd44-ctla4 bispecific antibodies
|
|
EP4103609A1
(en)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd7
|
|
EP4103612A1
(en)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispecific antibodies against cd9
|
|
CA3170833A1
(en)
|
2020-02-21 |
2021-08-26 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
|
KR20220143869A
(ko)
|
2020-02-21 |
2022-10-25 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
항-il-2 항체, 이의 항원-결합 단편 및 이의 의학적 용도
|
|
TWI908779B
(zh)
*
|
2020-03-17 |
2025-12-21 |
美商西雅圖免疫公司 |
引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
|
|
EP4121456A1
(en)
|
2020-03-18 |
2023-01-25 |
Genmab A/S |
Antibodies binding to b7h4
|
|
EP4126936A1
(en)
|
2020-03-27 |
2023-02-08 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
|
CN113461824A
(zh)
*
|
2020-03-31 |
2021-10-01 |
普米斯生物技术(珠海)有限公司 |
一种构建多特异性抗体的平台
|
|
BR112022022730A2
(pt)
|
2020-05-08 |
2023-02-14 |
Genmab As |
Método para tratar um linfoma não hodgkin de células b em um indivíduo humano
|
|
US20230174670A1
(en)
|
2020-05-14 |
2023-06-08 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
EP3915580A1
(en)
|
2020-05-29 |
2021-12-01 |
Numab Therapeutics AG |
Multispecific antibody
|
|
KR20230034361A
(ko)
|
2020-07-02 |
2023-03-09 |
베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 |
항-fxi/fxia 항체, 이의 항원-결합 단편, 및 이의 약제학적 용도
|
|
CA3184724A1
(en)
|
2020-07-27 |
2022-02-03 |
Wenming REN |
Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof
|
|
EP4192859A1
(en)
|
2020-08-06 |
2023-06-14 |
BioNTech SE |
Binding agents for coronavirus s protein
|
|
GB202012326D0
(en)
|
2020-08-07 |
2020-09-23 |
Citryll B V |
Diagnostic
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
EP4210746A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
|
US20240034812A1
(en)
|
2020-09-10 |
2024-02-01 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
US20230374158A1
(en)
|
2020-10-13 |
2023-11-23 |
Almirall, S.A. |
Bispecific molecules and methods of treatment using the same
|
|
US20230374148A1
(en)
|
2020-10-15 |
2023-11-23 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
|
EP3988568A1
(en)
|
2020-10-21 |
2022-04-27 |
Numab Therapeutics AG |
Combination treatment
|
|
CA3197465A1
(en)
|
2020-11-02 |
2022-05-05 |
UCB Biopharma SRL |
Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
|
|
KR20230117588A
(ko)
|
2020-12-07 |
2023-08-08 |
유씨비 바이오파마 에스알엘 |
다중특이적 항체 및 항체 조합
|
|
MX2023006649A
(es)
|
2020-12-07 |
2023-06-21 |
UCB Biopharma SRL |
Anticuerpos contra interleucina-22.
|
|
US20240392003A1
(en)
|
2021-02-02 |
2024-11-28 |
Numab Therapeutics AG |
Multispecific antibodies having specificity for ror1 and cd3
|
|
GB202102227D0
(en)
|
2021-02-17 |
2021-03-31 |
UCB Biopharma SRL |
Antibodies
|
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
EP4331603A4
(en)
|
2021-04-25 |
2025-04-02 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
ANTI-MASP2 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
|
|
EP4334355A1
(en)
|
2021-05-03 |
2024-03-13 |
UCB Biopharma SRL |
Antibodies
|
|
WO2022233931A1
(en)
|
2021-05-04 |
2022-11-10 |
Citryll B.V. |
Inhibition of eosinophilic traps
|
|
EP4085973A1
(en)
|
2021-05-04 |
2022-11-09 |
Citryll B.V. |
Inhibition of eosinophil extracellular traps
|
|
AR125815A1
(es)
|
2021-05-07 |
2023-08-16 |
Genmab As |
Composiciones farmacéuticas que comprenden anticuerpos biespecíficos que se unen a b7h4 y cd3
|
|
WO2022268740A1
(en)
|
2021-06-21 |
2022-12-29 |
Genmab A/S |
Combination dosage regime of cd137 and pd-l1 binding agents
|
|
EP4365200A4
(en)
|
2021-06-28 |
2025-04-09 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
ANTI-CD40 ANTIBODY, ANTIGEN-BINDING FRAGMENT AND MEDICAL USE THEREOF
|
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
|
CN113527503A
(zh)
*
|
2021-07-27 |
2021-10-22 |
福建医科大学 |
一种用于类风湿性关节炎的抗VEGF和TNF-α双特异性纳米抗体融合蛋白
|
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
|
EP4393949A4
(en)
|
2021-08-25 |
2025-01-08 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
PHARMACEUTICAL COMPOSITION WITH FUSION PROTEIN
|
|
CN117940453A
(zh)
|
2021-09-15 |
2024-04-26 |
江苏恒瑞医药股份有限公司 |
特异性结合pd-1的蛋白及其医药用途
|
|
AR127298A1
(es)
|
2021-10-08 |
2024-01-10 |
Genmab As |
Anticuerpos que se unen a cd30 y cd3
|
|
EP4183800A1
(en)
|
2021-11-19 |
2023-05-24 |
Medizinische Hochschule Hannover |
Novel sars-cov-2 neutralizing antibodies
|
|
MX2024009715A
(es)
|
2022-02-11 |
2024-08-19 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Inmunoconjugado y su uso del mismo.
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
|
WO2024038095A1
(en)
|
2022-08-16 |
2024-02-22 |
Iome Bio |
NOVEL ANTI-RGMb ANTIBODIES
|
|
CA3264339A1
(en)
|
2022-08-31 |
2024-03-07 |
Washington University |
Alphavirus antigen-binding molecules and their uses
|
|
GB202214756D0
(en)
|
2022-10-07 |
2022-11-23 |
Univ Oxford Innovation Ltd |
Product
|
|
GB202216284D0
(en)
|
2022-11-02 |
2022-12-14 |
Ucl Business Ltd |
Self-regulation
|
|
CA3273660A1
(en)
|
2022-11-28 |
2024-06-06 |
UCB Biopharma SRL |
TREATMENT FOR FIBROMYALGIA
|
|
JP2026502840A
(ja)
|
2022-12-28 |
2026-01-27 |
スゥジョウ サンカディア バイオファーマシューティカルズ カンパニー リミテッド |
Ｃｄ４０結合分子の組成物及び医薬的使用
|
|
JP2026510747A
(ja)
|
2023-03-15 |
2026-04-10 |
シャンハイ マブジェン バイオテック リミテッド |
Ｐｄ－１／ｐｖｒｉｇ／ｔｉｇｉｔ結合タンパク質を含む医薬組成物及びその医薬的使用
|
|
EP4442705A1
(en)
|
2023-04-03 |
2024-10-09 |
Citryll B.V. |
Dosage
|
|
CN121240884A
(zh)
|
2023-04-05 |
2025-12-30 |
根马布股份公司 |
包含与cd30和cd3结合的抗体的药用组合物
|
|
WO2025003280A1
(en)
|
2023-06-30 |
2025-01-02 |
Genmab A/S |
Antibodies binding to fibroblast activation protein alpha and death receptor 4
|
|
AU2024323336A1
(en)
*
|
2023-08-15 |
2026-02-26 |
Minghui Pharmaceutical (Hangzhou) Limited |
Single-domain antibody specifically binding to cdcp1 and use thereof
|
|
KR20260054696A
(ko)
|
2023-08-16 |
2026-04-22 |
상하이 맙젠 바이오텍 리미티드 |
면역접합체를 포함하는 약학적 조성물 및 이의 용도
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
CN121986112A
(zh)
*
|
2023-09-22 |
2026-05-05 |
阿布林克斯有限公司 |
二价和多价白蛋白结合剂
|
|
GB202316779D0
(en)
|
2023-11-01 |
2023-12-13 |
Ucl Business Ltd |
Antigen binding protein
|
|
GB202318703D0
(en)
|
2023-12-07 |
2024-01-24 |
Citryll B V |
Diagnostic agent
|
|
GB202318820D0
(en)
|
2023-12-08 |
2024-01-24 |
UCB Biopharma SRL |
Antibodies
|
|
WO2025133290A1
(en)
|
2023-12-21 |
2025-06-26 |
Temper Bio |
Protein for immune regulation
|
|
TW202540204A
(zh)
|
2024-01-26 |
2025-10-16 |
西班牙商阿爾米雷爾有限公司 |
雙特異性分子及使用其的治療方法
|
|
GB202403366D0
(en)
|
2024-03-08 |
2024-04-24 |
Univ Oxford Innovation Ltd |
Product
|
|
WO2025196217A1
(en)
|
2024-03-21 |
2025-09-25 |
UCB Biopharma SRL |
Treatment of tauopathies with tau-binding antibodies
|
|
WO2025238133A1
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Multispecific antibody with binding specificity for il-11 and il-17
|
|
TW202547865A
(zh)
|
2024-05-17 |
2025-12-16 |
比利時商Ｕｃｂ生物製藥公司 |
具有il-11結合特異性的抗體
|
|
TW202606759A
(zh)
|
2024-08-02 |
2026-02-16 |
比利時商Ｕｃｂ生物製藥公司 |
抗Gremlin-1抗體的調配物
|
|
WO2026057816A1
(en)
|
2024-09-13 |
2026-03-19 |
UCB Biopharma SRL |
Treatment of tauopathies with tau-binding antibodies
|